Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes
90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the …

The development of immune checkpoint inhibitors [monoclonal antibodies targeting
cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Background Blocking the interaction between PD-1 and its ligands is a promising treatment
strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour …

The balance between Th17 cells and regulatory T cells (Tregs) has emerged as a prominent
factor in regulating autoimmunity and cancer. Th17 cells are vital for host defense against …

A unique collaboration of multidisciplinary experts from the European Dermatology Forum,
the European Association of Dermato-Oncology and the European Organization for …

Importance Immune checkpoint inhibitors (ICIs) have emerged as active therapies for a
variety of cancers. Cutaneous toxicities are common immune-related adverse events and …

The immune checkpoint targeted agents, anti–cytotoxic T-lymphocyte–associated antigen 4
(CTLA-4) and anti–programed cell death 1 (PD-1) or anti–programmed death ligand 1 (PD …

Immunomodulatory drugs that leverages host immune mechanisms to destroy tumor cells
have been met with great promise in the treatment of cancer. Immunotherapy, targeting …

Background Bullous disorders associated with anti–programmed cell death 1 (PD-
1)/programmed cell death ligand 1 (PD-L1) therapy are increasingly reported and may pose …